Adcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosedV
Venrock
Activity from announced rounds
Activity in this selectionEurope
Venrock is the venture manager whose own Encoded portfolio identifies investor Bryan Roberts.
Recorded funding activity
Encoded develops neurological gene therapies. Other recorded companies include Gitar’s software-review agents and Adcendo’s targeted cancer medicines. Venrock Healthcare Capital Partners remains a separate manager identity.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $75M 1 disclosed · full round size, not this investor’s share